Last reviewed · How we verify
NCT05755373: FLAME-ASCVD
A Multinational Survey-based Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Cardiologists
trial testing No treatment given in Atherosclerotic Cardiovascular Disease (ASCVD) in 602 participants. Completed in 15 May 2023.
15 May 2023
Quick facts
| Lead sponsor | Novo Nordisk A/S |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 602 |
| Start date | 24 March 2023 |
| Primary completion | 15 May 2023 |
| Estimated completion | 15 May 2023 |
| Sites | 1 location across India |
Drugs / interventions tested
- No treatment given — full drug profile →
Conditions studied
- Atherosclerotic Cardiovascular Disease (ASCVD) — all drugs for Atherosclerotic Cardiovascular Disease (ASCVD) →
- Chronic Kidney Disease (CKD) — all drugs for Chronic Kidney Disease (CKD) →
Sponsor
Novo Nordisk A/S — full company profile →
Who can join
18 and older, any sex, with Atherosclerotic Cardiovascular Disease (ASCVD) or Chronic Kidney Disease (CKD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this survey is to collect information for scientific research and to better understand the role of systemic inflammation in identification, treatment and management of patients with ASCVD and CKD. This study is a cross-sectional design conducted among cardiologists in United Kingdom, Italy, Germany, Brazil, Saudi Arabia, Japan, Australia, China, India and France, treating ASCVD and CKD patients. Study participants will be recruited to complete an approximately 20-minute self-administered online survey. Recruitment will be conducted through email and phone. Data is collected though online data collection using a programmed survey.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Awareness and Perceptions towards the Role of Systemic Inflammation and High-Sensitivity C-reactive Protein as a Biomarker in Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease: The Multinational FLAME-ASCVD Survey amongst Cardiologists.
Marx N, Komuro I, Prasad P, Qian J, et al · · 2024 · cited 3× · PMID 39735352 · DOI 10.5334/gh.1382
Verify or expand the search:
- PubMed search for NCT05755373
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No treatment given
Trials testing the same drug.
- NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
- NCT07358052 — Current Status of Cardiovascular Diseases in Chinese Overweight/ Obesity Population: An Epidemiological Study (COPE） · completed
- NCT07201831 — A Multi-country, Cross-sectional Quantitative Study Exploring Awareness, Understanding, and Perceptions of the Relation · completed
- NCT07154238 — Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sec · enrolling by invitation
- NCT07160829 — Focus on Levels of Awareness and Perceptions Regarding hsCRP in Identifying Systemic Inflammation in ASCVD, CKD and Hear · completed
Other recruiting trials for Atherosclerotic Cardiovascular Disease (ASCVD)
Currently open trials in the same condition.
- NCT06960902 — Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO-FH Study) · NA · recruiting
- NCT06813911 — Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Establish · Phase 3 · recruiting
- NCT07315997 — The Coronary Artery Calcium and Troponins in Rheumatoid Arthritis (CAT-RA) Study · recruiting
Other Novo Nordisk A/S trials
Trials by the same sponsor.
- NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
- NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
- NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
- NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
- NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05755373 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
- Last refreshed: 9 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05755373.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing